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assessment of heterogeneity  (I2) and publication bias 
(Begg’s test).
Results Out of 2636 articles, 35 case series were included 
in the meta-analysis. Results are described for fixed-effect 
models. For patients with impaired visual acuity, only one 
study reported complete recovery (27.2%). Pooled preva-
lence for improvement was 67.5% (95% CI = 59.1–75.0%), 
but with considerable heterogeneity  (I2: 86.0%), and 4.50% 
(95% CI = 1.80–10.8%) for patients experiencing deteriora-
tion. For patients with visual field deficits, the prevalence 
was 40.4% (95% CI = 34.8–46.3%) for complete recovery, 
80.8% (95% CI = 77.7–83.6%) for improvement, and 2.3% 
(95% CI = 1.1–4.7%) for deterioration. For the unspecified 
visual outcomes, pooled prevalence of complete recov-
ery was 32.9% (95% CI: 28.5–37.7%), but with consider-
able heterogeneity  (I2 = 84.2%). The prevalence was 80.9% 
(95% CI = 77.9–83.6) for improvement and 2.00% (95% 
CI = 1.10–3.40%) for deterioration. Random-effect models 
yielded similar results. Publication bias was non-significant 
for all the outcomes.
Conclusion While visual deficits improved after EETS 
in the majority of patients, complete recovery was only 
achieved in less than half of the patients and some patients 
even suffered from visual deterioration.
Keywords Endonasal endoscopic surgery · Pituitary 
adenoma · Visual outcomes · Meta-analysis
Introduction
Pituitary adenomas are the second mos t prevalent cen-
tral nervous system tumors (24.6%) [1]. Patients often 
present with visual deficits related to chiasmal compres-
sion such as visual field deficits (46–75%) and decreased 
Abstract 
Purpose Patients with pituitary adenomas often present 
with visual deficits. While the aim of endoscopic endonasal 
transsphenoidal surgery (EETS) is to improve these defi-
cits, permanent worsening is a possible outcome. The aim 
of this meta-analysis was to evaluate the effect of EETS for 
pituitary adenomas on visual outcomes.
Methods A meta-analysis was conducted according to 
the PRISMA guidelines. Pooled prevalence was calculated 
for complete recovery, improvement, and deterioration of 
visual field deficits, visual acuity and unspecified visual 
function in fixed- and random-effect models, including 
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visual acuity (14–44%) [2–6]. Both of these presenting 
symptoms are associated with a lower health-related 
quality of life (HRQoL) in this patient group and are 
therefore seen as a clear indication for surgery [4, 7].
While the aim of surgical resection in patients pre-
senting with visual deficits is to improve or halt further 
progression of these deficits, possible complications 
may result in permanent worsening of the same symp-
toms [3]. Since the introduction of endoscopic endona-
sal transsphenoidal surgery (EETS), postoperative visual 
outcomes have improved [5, 8, 9]. However, results of 
visual outcomes vary, and worsening of symptoms or 
even new deficits have been reported as well [10, 11]. 
As it is unclear what the effect of EETS is on visual out-
comes and which determinants may influence these out-
comes, variation in treatment strategy and timing of sur-
gery between practices has been reported [4, 12]. Some 
centers operate on pituitary adenomas only to alleviate 
current visual complaints, whereas others operate with 
the goal to prevent the development of future symptoms 
and progression of existing symptoms [4, 12].
Due to variation in treatment strategy, including tim-
ing of the procedure, visual function after endoscopic 
endonasal surgery for pituitary tumors may vary among 
patients. Therefore, the primary aim of this meta-anal-
ysis was to document more precise prevalence rates of 
postoperative improvement, complete recovery, and 
deterioration of visual function. The secondary aim of 
this study was to identify and assess determinants, espe-
cially the effect of surgical timing, of postoperative vis-
ual functioning.
Methods
Search strategy
This meta-analysis was performed in accordance with 
the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) statement [13]. After 
approval of the protocol, the following databases were 
searched on 07-08-2016 for relevant literature: PubMed, 
Embase, Cochrane, Central, CINANHL, PsycINFO, 
Academic Search Premier, ScienceDirect and Web 
of Science. The search strategy was based on the key-
words: “pituitary”, “endoscopic surgery” and “vision” 
and search terms to exclude studies with only animals, 
case reports and reviews (Supplementary Table  1). In 
addition, articles published before 1992 were excluded, 
as the first report on endoscopic endonasal pituitary sur-
gery was published in that year [14].
Paper selection
Titles and abstracts of articles were screened by two inde-
pendent authors for eligibility. Discrepancies were solved 
by a third author. Inclusion criteria were original peer-
reviewed articles in English, describing visual outcomes 
after endoscopic endonasal transsphenoidal pituitary ade-
noma surgery in patients older than 18 years. Articles that 
described outcomes after pituitary apoplexy and results 
of resection with extended endoscopic approaches were 
excluded. Furthermore, case-reports, congress abstracts, 
commentaries and reviews were excluded. If there were 
overlapping cohorts, only the largest cohort was included 
in the review. References of selected articles were checked 
for possible relevant studies. Disagreements were solved by 
discussion.
Data extraction
The following study characteristics were extracted from the 
full text articles: study design, main in- and exclusion cri-
teria, number of participants, gender, age, tumor subtypes, 
tumor size, and gross total resection rate. Regarding the 
visual outcomes, the following data were extracted: time 
between diagnosis and surgery, and pre- and postoperative 
visual outcomes. If visual outcomes were specified by the 
included studies for visual acuity and visual field deficits, 
the number of patients that showed complete recovery, 
general improvement or deterioration was extracted for 
these specific outcomes. If outcomes were not specified for 
visual acuity and visual fields deficits, data were extracted 
for unspecified visual function. In addition, determinants 
of postoperative visual outcomes were extracted from the 
included studies.
Study quality assessment of the included studies
Study quality was assessed using the Newcastle–Ottawa 
scale for cohort studies and the criteria for case series by 
Cowley [15, 16]. Criteria of both scales were combined 
and adapted for the subject of this study (Supplementary 
Table 2). Studies were assessed for patient selection (max. 
4 points), exposure of intervention (i.e. surgery: max. 1 
point) and outcome assessment (max. 5 points).
Meta-analysis
Pooled prevalence of complete recovery, improve-
ment and deterioration were assessed for visual acuity, 
visual fields deficits or unspecified visual functioning 
using Comprehensive meta-analysis  CMA© version 3. 
Fixed overall prevalence rates were calculated using the 
inverse variance method and random prevalence rates 
541Pituitary (2017) 20:539–552 
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using the method of DerSimonian and Laird [17]. Fixed 
prevalence rates were reported in text if not further spec-
ified. Study heterogeneity was assessed by calculating 
I-squared values. An I-squared value >40% was deemed 
high. Furthermore, publication bias was assessed with 
Begg’s test and Egger’s test. In case of significant pub-
lication bias, a corrected fixed prevalence rate was cal-
culated using the trim and fill method [18]. Meta-regres-
sion on covariates such as study characteristics was not 
possible, as these were not reported in all studies. There-
fore, factors influencing visual outcomes as described 
in the included articles are qualitatively described. To 
assess the effect of study quality on the reported visual 
outcomes, a meta-regression was conducted with study 
quality as covariate.
Results
Study characteristics
After removing duplicates, 2636 articles were identified. 
After screening for title and abstract 2398 articles were 
excluded and 238 articles were reviewed full text. After-
wards, 35 studies were included in the review and meta-
analysis (Fig. 1) [5, 6, 8–11, 19–47]. All studies were ret-
rospective case series. The total number of participants 
ranged between 10 and 313 (median: 45). Mean age per 
study ranged between 35.5 and 72.5 years (median: 50) 
and the percentage female patients ranged between 15 and 
100% (median: 45%). Seven studies included only non-
functioning pituitary adenoma patients [28, 31, 33, 37, 40, 
42, 46]. Gross total resection grades were reported in 26 
studies and ranged between 14 and 91% (median: 63.5%) 
Fig. 1  Flowchart of search 
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(Table 1) [5, 6, 8, 11, 20, 21, 24–26, 28–34, 36–40, 42, 43, 
46, 47].
Visual outcomes
Results of postoperative visual outcomes are reported in 
Supplementary Table  2 for each study. Pooled prevalence 
rates for visual acuity, visual fields deficits, and unspecified 
visual functioning are reported in Table 2.
Visual acuity
Patients presented with visual acuity complaints in 14–84% 
of cases (Supplementary Table 3) [5, 36]. Ten studies eval-
uated postoperative visual acuity in their case series [5, 6, 
9, 20, 22, 25, 30, 36, 37, 46]. Pooled prevalence of overall 
improvement was 67.5% (95% CI: 59.1–75.0%,  I2: 86.0%, 
n = 163/219). Pooled prevalence of deterioration was 4.5% 
(95% CI: 1.8–10.8%,  I2: 0.00%, n = 3/122) (Table 2). One 
study reported complete recovery of visual acuity in 9 out 
of 33 patients [46]. No significant publication bias was 
identified. One study described a significant improvement 
in mean Snellen test score for both the right eye [preop-
erative: 0.72 (SD: 0.14); postoperative 0.83 (SD: 0.16); 
p < 0.01] and left eye [preoperative: 0.76 (SD: 0.16); post-
operative 0.85 (SD: 0.14); p = 0.04] [19].
Visual field deficit
Patients presented with visual field deficits in 28–100% of 
cases (Supplementary Table 3) [5, 41, 42]. Nineteen studies 
described outcomes of visual field deficits [5, 8–11, 19–23, 
27–29, 36, 37, 41, 42, 44, 46]. The overall prevalence was 
40.4% (95% CI: 34.8–46.3%,  I2: 0.00%, n = 122/346) for 
complete recovery, 80.8% (95% CI: 77.7–83.6%,  I2: 62.3%, 
n = 678/817) for overall improvement, and 2.3% (95% CI: 
1.1–4.7%,  I2: 0.00%, n = 3/398) for deterioration in which 
patients showed a decreased visual functioning postopera-
tively (Table  2). One study described a mean Goldmann 
Humphrey VFD score of 1.1 (SD: 1.1) preoperatively, com-
pared to 0.2 (SD: 0.5) postoperatively, indicating a clear 
improvement (p < 0.05) [41]. No significant publication 
bias was identified.
Unspecified vision
In studies that did not specify type of visual problems, 
17–100% of the patients presented with visual prob-
lems (Supplementary Table  3) [31, 39]. Unspecified out-
comes of visual improvement were reported in 13 studies 
[24, 26, 31–35, 38–40, 43, 45, 47]. Pooled prevalence for 
complete recovery was 32.9% (95% CI: 28.5–37.7%,  I2: 
84.2%, n = 139/416). Improvement was reported in 80.9% 
(95% CI: 77.9–83.6%,  I2: 38.8%, n = 648/788). Dete-
rioration occurred in 2.0% (95% CI: 1.1–3.4%,  I2: 0.00%, 
n = 10/721). No significant publication bias was identified.
Study-quality assessment
The majority of studies (83.3%) had a high risk of bias due 
to suboptimal methodology or poor reporting (Table  3). 
While all studies clearly described the surgical approach 
(exposure of intervention), only one study scored all points 
for selection and description of included patients and only 
one study for the description, interpretation, and discussion 
of the outcomes (outcome assessment) [31, 40]. However, 
study quality was associated with visual outcomes in a 
meta-regression (all p < 0.05).
Factors influencing visual outcomes
Factors affecting postoperative visual functioning may be 
procedure, symptom, tumor or patient related. Regarding 
procedural circumstances, increasing surgeon experience 
was positively associated with postoperative visual field 
deficit improvement in three studies (early groups: 75–86%; 
late groups: 90–100%) [5, 8, 9]. Furthermore, extend of 
resection was associated with poor visual field deficit out-
comes in one study (p = 0.01), while three studies found no 
significant relation, both for visual acuity and visual field 
deficit outcomes [22, 36, 40, 42].
Regarding symptoms, longer duration of visual field 
deficits led to worse visual outcomes in two studies, while 
one study did not find a relation [19, 42]. In the first study, 
patients with complete recovery had a shorter visual field 
deficit symptoms (14.7 weeks, SD: 10.5), than patients with 
partial recovery (50.1 weeks, SD: 29.1) and patients with 
no recovery (92.4 weeks, SD: 15.4) (p < 0.01) [19]. Also, 
one study demonstrated that severity of visual field deficit 
symptoms was associated with worse visual outcomes in 
a multivariable analysis [48]. Finally, patients with bilat-
eral visual field deficit had significantly better outcomes 
(p = 0.025) [22].
Regarding tumor related factors, functioning (growth 
hormone producing tumors: 71%, prolactinomas 63–75%) 
and non-functioning pituitary tumors (43–100%) seem to 
have similar visual outcomes with regard to visual field def-
icits and unspecified visual improvement [8, 10, 19, 28, 31, 
32, 37, 42, 44, 46]. One study found a significant relation 
between suprasellar extension and worse visual outcomes 
based on patient reported outcome measures, where another 
does not find a relation with visual field deficits [42, 49]. 
Also, tumor size does not seem to have a great influence on 
both postoperative visual acuity and visual field deficits as 
seen in two studies with larger tumors (>3 cm in diameter 
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and a volume >10 cm3) where improvement was seen in 69 
and 70% of cases [22, 24].
With regard to patient characteristics, the influence of 
age on visual outcomes shows conflicting results in four 
studies [47]. One group reported no significant differences 
between patients younger and older than 65 for unspecified 
visual symptoms [33, 40, 47, 48]. Similarly, two studies 
reported outcomes of patients older than 65 and 70 years 
with unspecified visual improvement in 71 and 87% of 
cases, respectively [33, 40]. However, one study associated 
younger age with visual field deficit improvement in a mul-
tivariate analysis [48].
Discussion
This meta-analysis showed that pituitary adenoma resec-
tion in patients with preoperative visual symptoms consid-
erably improves these symptoms in the majority of cases. 
Furthermore, up to 30% of patients have complete recovery 
of their vision. However, deterioration is not uncommon 
either, occurring in up to 4% of cases. While the consider-
able improvement of visual deficits is a clear indication for 
EETS in patients with pituitary adenomas, a better under-
standing of the factors that influence these outcomes may 
result in even better postoperative results. These factors can 
be procedure, symptom, tumor, and patient related.
Factors related to the procedure may influence visual 
outcomes in several ways, such as experience with EETS. 
Although visual outcomes may improve with increased 
experience, this may be balanced out by selection of more 
complex cases. Despite this, surgeon experience was 
found to be a significant influence on visual outcomes in 
three studies [5, 8, 9]. However, gross total resection was 
not associated with improved visual outcomes, probably 
because also partial resection will result in decompression 
of the optic nerve/chiasm [22, 36, 40, 42]. Besides surgeon 
experience, surgeon preference for preventive surgery or 
surgery after development of visual deficits may also result 
in different outcomes.
Apart from procedure related factors, the duration and 
severity of preoperative visual symptoms may also affect 
postoperative outcomes [19, 48, 50]. For instance, one 
study found that patients with long lasting (≥1 year) preop-
erative visual symptoms showed significantly worse visual 
outcomes after microscopic resection [50]. As the timing of 
the postoperative visual examination varied greatly among 
the studies and visual symptoms may improve after longer 
periods of time, this may also be of influence [9–11, 22, 31, 
34, 37, 43, 51, 52].
Several patient and tumor characteristics may also affect 
visual outcomes. Increasing age does not seem to be asso-
ciated with worse outcomes [33, 40, 47, 48]. Tumor size 
and whether the tumor is hormone producing does not 
seem to greatly alter the visual outcomes [10, 20, 22–25, 
36, 38, 39]. The lack of influence from tumor size on visual 
outcomes may possibly be explained by the slow growth 
of these tumors, which gives the optic nerve/chiasm time 
to adapt. However, indication and aim of surgery for func-
tioning and non-functioning pituitary adenomas differs 
principally, as surgical indication for functioning pituitary 
adenomas is often not visual deficits. Therefore, different 
visual outcomes of surgery may be expected when compar-
ing these two groups.
One other meta-analysis for pituitary adenomas by DeK-
lotz et  al. reported an overall visual improvement of 71% 
Table 2  Outcomes of the meta-analysis
a Complete restoration of visual acuity was only reported in one study and therefore a meta-analysis was not possible
Fixed model 
prevalence rate 
(%)
95% CI (%) Random model 
prevalence rate 
(%)
95% CI (%) I-squared 
value (%)
p value 
heterogene-
ity
Egger’s test 
(p value)
Begg’s 
test (p 
value)
Visual acuity
 Improvement 67.5 59.1–75.0 77.2 54.4–90.6 86.0 <0.01 0.22 0.14
 Deterioration 4.5 1.8–10.8 4.5 1.8–10.8 0.00 0.62 1.00 0.49
 Complete  restorationa
Visual field deficit
 Improvement 80.8 77.7–83.6 83.0 77.1–87.7 62.3 <0.01 0.25 0.14
 Deterioration 2.3 1.1–4.7 2.3 1.1–4.7 0.00 0.93 0.21 0.16
 Complete restoration 40.4 34.8–46.3 37.8 26.4–50.8 0.00 73.2 0.72 0.40
Unspecified vision
 Improvement 80.9 77.9–83.6 81.7 77.1–85.6 38.8 0.08 0.10 0.15
 Deterioration 2.0 1.1–3.4 2.0 1.1–3.4 0.00 0.96 1.00 0.74
 Complete restoration 32.9 18.5–37.7 39.6 23.2–58.6 84.2 <0.01 0.50 0.53
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(95% CI: 59–83%) in patients operated endoscopically 
based on nine studies, which is similar to our findings. This 
was also significantly higher than the patients operated 
microscopically (56%, 95% CI: 40–72%) [53].
Several other tumors in the sellar region may cause 
impaired vision. Patients with meningiomas showed 
improvement of vision after endoscopic resection in 87% 
of cases in one meta-analysis [54]. Another review evalu-
ating anterior skull base meningiomas reported improve-
ment in 69.1% of cases, but deterioration in 12.7% of cases, 
the latter being considerably higher than our findings [55]. 
A meta-analysis of visual outcomes after endoscopic sur-
gery for craniopharyngioma showed improvement in 
56.2% and deterioration 1.7% of cases [56]. Similarly, 
Table 3  Study quality 
assessment Author (year) Selection (max. 4 points)
Exposure (max. 
1 points)
Outcome (max. 
5 points)
Total 
points 
(max. 10)
Visual acuity and visual field studies
 Bokhari (2013) 2 1 3 6
 Campbell (2010) 2 1 3 6
 Chabot (2015) 3 1 1 7
 Juraschka (2014) 3 1 2 6
 Karppinen (2015) 3 1 4 8
 Yildrim (2016) 3 1 2 6
Visual acuity studies
 Constantino (2016) [25] 3 1 1 5
 De Witte (2011) [6] 2 1 2 5
 Fan (2014) [30] 1 1 1 3
Visual field studies
 Anik (2011) [19] 3 1 4 8
 Akin (2016) [10] 3 1 2 6
 Cappabianca (1999) [21] 2 1 1 4
 Chi (2013) [8] 1 1 2 4
 Cho (2002) [23] 3 1 1 5
 Dallapiazza (2015) [28] 3 1 1 5
 Dehdashti (2008) [29] 2 1 2 5
 D’Haens (2009) [27] 2 1 2 5
 Leach (2010) [9] 1 1 3 5
 Minet (2008) [41] 2 1 3 6
 Nakao (2011) [42] 2 1 3 6
 Paluzzi (2014) [11] 2 1 4 7
 Sheehan (1999) [44] 2 1 3 6
Visual function, unspecified
 Chohan (2016) [24] 3 1 1 5
 Cusimano (2012) [26] 3 1 1 5
 Gondim (2014) [32] 2 1 5 7
 Gondim (2015) [33] 2 1 1 4
 Ferreli (2014) [31] 3 1 1 5
 Han (2013) [34] 3 1 2 6
 Jho (1997) [35] 3 1 2 5
 Koutourousiou (2013) [38] 2 1 2 5
 Kuo (2016) [39] 3 1 2 6
 Marenco (2011) [40] 4 1 3 8
 Sabry (2015) [43] 2 1 3 6
 Wongsirisuwan (2014) [45] 3 1 1 5
 Zhan (2015) [47] 1 1 2 4
Median scores 2 points 1 point 2 points 6 points
Studies scoring maximum points 2.8% 100% 2.8%
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another meta-analysis for craniopharyngiomas even found 
an improvement in 85.5% of cases and deterioration in 
2.3% [57]. With regard to this variation in results, it is not 
entirely unlikely that different tumors with different char-
acteristics offer different visual outcomes after endoscopic 
resection. As a result, while meningioma resection seems 
to be associated with superior visual outcomes compared 
pituitary adenoma resection, craniopharyngioma resection 
seems to offer slightly inferior outcomes [54, 56, 57].
While there are over 30 existing questionnaires meas-
uring patient-reported visual function and vision-related 
HRQoL, no studies were identified measuring these out-
comes in endoscopically operated pituitary patients [58]. 
Measurement of patient-reported visual function and 
HRQoL is of added value as it is known that physician-
reported outcomes and patient-reported outcomes may 
poorly correlate and because these questionnaires measure 
not only visual deficits but also consequences of these defi-
cits on daily life [59].
The main limitation of this meta-analysis is the inabil-
ity to examine reported patient characteristics as a possible 
source of heterogeneity, because not all pituitary adenoma 
patients present with visual problems. Patient character-
istics were reported for the whole population, not specifi-
cally for patient presenting with visual symptoms. Thus, 
no clear factors were identified that could contribute to bet-
ter outcomes. Furthermore, as the studies identified only 
described visual recovery with relatively short follow-up, 
long-term visual outcomes could not be studied.
Even though our study shows that EETS for pituitary 
adenoma improves visual complaints for most patients, 
incomplete recovery or even worsening of symptoms is not 
uncommon. Therefore, future research should be focused 
on identifying risk factors for incomplete recovery or even 
deterioration of vision with adequate follow-up. The role 
of surgical experience, patient characteristics, tumor char-
acteristics, and severity and duration of visual symptoms 
should be studied (preferably prospectively) to identify the 
optimal timing of, and indications for, EETS for pituitary 
adenomas.
Conclusion
ETTS for pituitary adenomas improves visual deficits 
considerably in the majority of cases in the postoperative 
period. However, EETS only results in complete recovery 
in 30–40% of cases and 4% of patients even experience 
deterioration of visual symptoms. This is particularly rel-
evant, as visual symptoms often form the indication of sur-
gery. Future research should therefore focus on identifying 
risk factors for incomplete recovery and deterioration of 
vision in order to improve visual outcomes.
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